Orly Sarid

Nutrition is being increasingly recognized as a modifiable adjuvant factor in symptom management, yet few studies have examined the direct contribution of fruit consumption to chronic disease outcomes. The existing research largely emphasizes broad dietary patterns or isolated nutrients, rather than specific fruit species and their complex bioactive profiles. This gap is particularly evident in conditions lacking disease-specific pharmacological treatments, such as fibromyalgia syndrome (FMS), where patients often depend on lifestyle adjustments and complementary strategies for symptom relief. The therapeutic use of fruits presents methodological challenges, as their biochemical composition is strongly influenced by abiotic and biotic stresses, seasonal and regional variations, as well as post-harvest handling and storage. Such variability complicates reproducibility and obscures causal links in clinical research. While reductionist approaches that isolate single compounds offer dose control, they risk losing synergistic effects inherent to whole fruits. Conversely, whole-fruit consumption preserves integrative complexity but introduces variability. Overcoming these limitations requires rigorous standardization across agricultural, nutritional, and clinical domains, accurate species and cultivar identification, controlled cultivation conditions, chemical fingerprinting, and biomarker validation. In this context, cacti fruits such as Opuntia ficus-indica (prickly pear), which is rich in betalains and polyphenols, emerge as promise adjuvant agents for FMS symptom management. We propose a protocol designed to systematically evaluate their efficacy and feasibility in clinical application, aiming to strengthen the reliability and accuracy of research outcomes.